Results 181 to 190 of about 22,482 (226)

Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison. [PDF]

Adv Ther
Cortesi PA, Mezghani M, Alshaikheid M, Lunk I, D'Orsi MF, Zurria M, Bandello F.   +6 more
europepmc   +1 more source

Error in Figure 1.

JAMA Ophthalmol
europepmc   +1 more source

Aflibercept

Reactions Weekly, 2022
Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy.
Sorhaitz, Winston, Stringham, Jack, Adams, Bryan S.   +2 more
core   +7 more sources

Some of the next articles are maybe not open access.

Related searches:

Aflibercept

Reactions Weekly, 2014
exaly   +2 more sources

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.

The Lancet
BACKGROUND Intravitreal aflibercept 8 mg could improve treatment outcomes and provide sustained disease control in patients with neovascular age-related macular degeneration (nAMD), with extended dosing compared with aflibercept 2 mg. METHODS PULSAR is
P. Lanzetta, J. Korobelnik, J. Heier, Sergio Leal, F. Holz, W. Clark, David A. Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, T. Schmelter, U. Schmidt-Ott, Xin Zhang, R. Vitti, Karen W. Chu, Kim Reed, Rohini Rao, R. Bhore, Yenchieh Cheng, Wei Sun, Boaz Hirshberg, G. Yancopoulos, T. Wong   +23 more
semanticscholar   +1 more source

Noninfectious Intraocular Inflammation After Intravitreal Aflibercept.

JAMA ophthalmology
Importance Aflibercept, 8 mg, is an anti-vascular endothelial growth factor (VEGF) formulation for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Karoline E Binder, Nathalie Bleidißel, Peter Charbel Issa, M. Maier, Leonard Coulibaly   +4 more
semanticscholar   +1 more source

Aflibercept

Reactions Weekly
  +10 more sources

Real-world outcomes of treatment resistant neovascular-age related macular degeneration switched from Aflibercept to Faricimab.

Ophthalmology Retina, 2023
PURPOSE While previous studies have demonstrated the efficacy of Faricimab in treatment-naïve nAMD patients, its outcomes in patients switched from Aflibercept are less understood.
R. Raimondi, Tina Falfeli, Anna Bogdanova-Bennet, D. Varma, M. Habib, Ajay Kotagiri, David H. Steel, M. Grinton   +7 more
semanticscholar   +1 more source